Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.84 and traded as high as $0.9431. Brainstorm Cell Therapeutics shares last traded at $0.9088, with a volume of 78,591 shares.
Brainstorm Cell Therapeutics Stock Performance
The company has a 50 day moving average price of $0.95 and a 200 day moving average price of $0.84. The company has a market capitalization of $12.96 million, a price-to-earnings ratio of -0.27 and a beta of 0.28.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last issued its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Research analysts forecast that Brainstorm Cell Therapeutics Inc. will post -3.01 EPS for the current year.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc is a biotechnology company focused on developing cell-based therapies for neurodegenerative diseases. The company’s technology platform uses autologous mesenchymal stem cells, derived from a patient’s bone marrow and induced to produce neurotrophic factors that may support nerve-cell survival and repair.
Its lead product candidate, NurOwn, also known as debamestrocel or MSC-NTF cells, is being developed primarily for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis.
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
